
New radiopharma Actithera emerges with $75.5m in financing
A new player in radioligand therapies (RLTs), Norway and US-based Actithera, has arrived on the scene with $75.5 million in first-round financing and a lead asset for cancer in preclinical development. The proceeds will be used to move the RLT – which …